Sonias primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Dan Guglielmo is IT Operations Associate at RA Capital Management. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. Prior to this role, Cristina mapped a number of competitive landscapes, including respiratory, allergic, and infectious disease conditions. Copyright 2023 Surperformance. Soumya spent time as an EIR at IncTank Ventures, where he worked on multiple company creations. Emily started her career in strategy consulting at Frankel Group. Tess works on both public and private investments and serves on several company boards. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. James McArthur is an Advisor for RA Capital Management. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Joeys primary responsibility is to manage workflows for investor transaction processing and investor reporting in collaboration with the fund's administrator. Sadik holds a bachelor of science degree in Cell and Molecular Biology from Tulane University, and earned his PhD in Microbiology and Immunology from Louisiana State University. Michael is the Chief Financial Officer at RA Capital Management. In this role, he propelled the company to the next stage of growth and increased shareholder value by altering the course of this formerly research-based company to prioritize innovation, speed to commercialization, and culture transformation. as a Staff Accountant. A trained cardiologist, he has held academic faculty positions at the University of California, San Francisco (UCSF) and the University of Texas Southwestern Medical Center. Drew has a BS in Chemical Engineering from University of Virginia and a PhD in Chemical Engineering from Massachusetts Institute of Technology. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. Peter's age is in line with some of the older Vanderpump Rules cast members, like Jax, Tom Sandoval, and Tom Schwartz. He worked previously at Global Prior Art, an intellectual property analysis firm, as a Partner and the Director of the Life Sciences Division. Davids primary responsibility is to oversee the development and implementation of treasury functions for the firm. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. He has served on the Board of Directors of Sojournix, Inc., AltusPharmaceuticals (Nasdaq: ALTU) and the CellScape Corporation. Peter Kolchinsky | Greenwich Economic Forum Harveys primary responsibility is to oversee all accounting related activities for the firm. Prior RA, Cony was Executive Vice President and Chief Business Officer at Schrdinger for eight years, responsible for business development involving strategic collaborations and new company formation as well as software sales in the US and Japan. Alonso was also a chemistry professor at the Universidad de los Andes in Colombia. Katherines primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. Kriti previously served as Co-Director and Regional Director, South Asia for MIT Hacking Medicine. Cameron has a BA in Neurobiology from Harvard University. Previously, Emily spent over seven years at Celgene Corporation in positions of increasing responsibility in business development, marketing, operations, and as Principal to the Chairman and CEO. Rajeev Shah is a Managing Partner at RA Capital Management. Alyssas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to joining RA, Michael was Associate Vice President at Merck Research Labs. Priscilla previously held a Senior Scientist role at Sanofi. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, andWerewolf Therapeutics. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Toms primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Nate conducts due diligence on biotechnology companies at RA Capital and serves as a Board Director for The Covid Apollo Project and Nucleix. Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Kate McKenna is a Compliance Associate at RA Capital Management. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. TJ is a Senior Fund Accountant at RA Capital Management. Peter Pan & Wendy review - Jude Law has fun in a so-so reinvention Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. Emory Werner is an Associate with the TechAtlas division of RA Capital Management. Laura is an Executive Assistant at RA Capital Management. Prior to Catamaran, Mark served as Vice President, Legal Affairs at Rubius Therapeutics where he was responsible for leading internal legal activities in support of Rubius IPO and its growth to a clinical-stage company. In this role, he will work to evaluate and incubate early-stage therapeutic programs. Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). He served on the Scientific Advisory Boards of multiple companies including DNA Script, Danaher Life Sciences, and CircBio. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. Finally, they made it to the Boston. Peter Kolchinsky 285 Followers Scientist turned biotech investor, always learning, guided by fatherhood, share The Economist's world view, inspired to write by Hamilton's Federalist Papers. Alyssa Larson is an Associate Director within the TechAtlas division at RA Capital Management. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. Max DeNies is a Senior Associate with the TechAtlas division of RA Capital Management. He holds a Masters degree in Software Engineering from Brandeis University and a BA in Psychology from Providence College. Prior to RA, Dan spent three years in Systems Engineer and Technical Consultant roles at Withum Smith + Brown, where he provided cloud and hybrid implementation guidance for clients within industries such as healthcare, construction, and fitness. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners within RAVen. Peter Kolchinsky - RA Capital Management - Insider Monkey Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions. Senior Research Assistant, Venture Analytics. Sri Mahendra is a Senior Software Engineer at RA Capital Management. Priscillas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Fuad Naser is a Senior Associate with the TechAtlas division of RA Capital Management. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. She has twenty years of oncology experience with a strong focus on skin cancers, especially malignant melanoma. Special Projects Operations Manager/Chief of Staff. Biohaven Closes Second Tranche Of Private Placement And Appoints Two He was named an MIT Technology Review 100 innovators under 35 for his MIT Media Lab social enterprise, Dimagi, that has impacted millions with its mobile data collection platform. Natalie Camacho is an Executive Assistant at RA Ventures (RAVen). Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. Jake works on both public and private investments and serves as a Board Director for Xenikos, B.V, Tyra Biosciences, AavantiBio, and DiCE Molecules. Matt Beverly is a Senior Software Engineer at RA Capital Management. Harvey holds an MS in Finance from Bentley University McCallum Graduate School of Business and a BS in Corporate Finance and Accounting from Bentley University. In addition, Michael served on the firm's Luxembourg Board of Directors where he was responsible for accounting and financial reporting. Rez holds a BSc in biochemistry and PhD in cell biology from Newcastle University, UK. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. While at Tamarack, he managed coverage expansion into commercial-stage biotech, pharma, and specialty pharma sectors. Henry Stusnick is an Associate at RA Capital Management. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Peter Kolchinsky Net Worth | Age, Height, Weight, Dating And More Dans primary responsibility at RA Capital is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). Alyssa holds a BS in Biochemistry from the University of California, Santa Barbara, and a PhD in Biochemistry from MIT. Before Energetic, she was Head of Carbon Strategic Partnerships at Indigo Ag, where she led external innovation focused on solutions that minimize or sequester agricultural GHG emissions and deliver additional environmental, social, and economic co-benefits. Jesse Chen is an EIR at RA Capital. "Too old," said a man in his 70s. Before joining Rubius, Mark spent a decade launching, building or advising a portfolio of early-stage venture backed life-sciences companies, including Visterra, Living proof, Kala Pharmaceuticals, and Homology Medicines. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. David Migl is an Analyst on the Investment Team at RA Capital Management. Tyler Kowalski is an InteractiveDesigner at RA Capital Management. Rez has also held roles at Novartis, a virtual R&D company (BVD), and Xcellsyz Ltd, a UK-based start-up. Ally Boertzel is an Executive Assistant at RA Ventures (RAVen). Cosmas received his BS in Physics from Massachusetts Institute of Technology and his MD from Rutgers-New Jersey Medical School. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. Mariagrace previously worked as an Executive Assistant at MPM Capital. He oversees the firm's financial functions, including middle office operations, accounting, valuation, tax and financial reporting. Peter Pan has long been a character that audiences have held up a critical lens to, as the premise of an eternal boy who recruits isolated children naturally brings up some questions the more a person thinks about it. Maryann received her Bachelor of Science in English from Northeastern University. Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. Scott received his Bachelor of Science from the University of Illinois and his Ph.D. from the Massachusetts Institute of Technology. Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. Emily has her BS in Chemical Engineering from Rensselaer Polytechnic Institute in NY. Emorys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. Brackett Hardy is a Junior Associate with the TechAtlas division of RA Capital Management. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. Derek DiRocco is a Partner at RA Capital Management. Prior to Longitude Capital, Cristina held an Associate Analyst role in Biotechnology Equity Research at Cowen. In 2013 was awarded a Medical Research Council Clinical Scientist Fellowship. in Biochemistry and a Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada. At BPS, Joe provided technical support for teachers and staff and was Jamf certified to manage Apple products. He holds a BS in Biology from the College of William and Mary, where he studied the impact of ecological fragmentation on the prevalence of ticks and their bacterial pathogens. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. Most of Joels career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last five years as Vice President and Global Head of Discovery Chemistry, working across all therapeutic areas. Michael has a BS in Business Administration from Boston University with concentrations in Finance and Accounting. Peter Kolchinsky is a father, scientist, investor, teacher, and author. Peter Kolchinsky, RA Capital's founder and managing partner. She has a BA in Communication Studies from University of Minnesota, Twin Cities. Brian is a IT Operations Manager at RA Capital Management. Hearing the stories of how patients couldn't afford the . Alex is an Associate with the TechAtlas division of RA Capital Management. Tom holds a BS in Health Sciences with a minor in Journalism from Northeastern University. Any hedge fund managing over $100M is required to submit a 13F form to the SEC which lists their current holdings at the end of each fiscal quarter. Sams primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. in Business Administration in Management with a Minor in Biology from UMass Amherst Commonwealth Honors College. Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. Prior to this, she served as Director, Talent Acquisition and Operations at Flagship Pioneering, a role in which she built talent systems to support the growth of 30+ pre-series B biotech startup companies. She is on the Steering Committee for No Patient Left Behind, a non-profit focused on reforming American healthcare to make medicines affordable to patients and promote innovation. She previously served as Senior Vice President, R&D Operations & New Product Planning at Epirium Bio. She also has a Master's in Accounting from Boston College and is a CPA. Peyman holds a dual B.S. Joe holds a BS in Information Technology from UMass Lowell. Sadik and his teams have contributed to the successful BLA and MAA applications for three of the commercially available CAR-T therapies: Kymriah, Yescarta, and Tecartus. Anurag works on both public and private investments with a focus on Healthcare, Technology, and Services. Rebecca conducts due diligence on biotechnology companies at RA Capital. Prior to MPM, Sarah was the General Counsel for Charles River Ventures and before that, at Palomar Medical Technologies. As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases.
Is Hyperloop Train Worth It Egg, Inc,
Ealing Council Rubbish Collection Bank Holiday,
Articles P
peter kolchinsky age